ClarWorks

Free audit · No signup

Tool Sprawl Risk Audit — Biotech

Find out how much spreadsheet and SaaS sprawl is costing Biotech — and where a purpose-built internal tool pays off.

Signs of tool sprawl in Biotech

  • R&D timelines are 10-15 years and the cost per approved drug is in the billions — every operating decision is filtered through 'how does this affect time-to-IND, time-to-readout, time-to-NDA'.
  • FDA and EMA regulatory readiness is non-negotiable — the IND, the NDA, the BLA, and every clinical trial design has to survive regulator examination, and the documentation infrastructure has to be audit-ready continuously.
  • Clinical trial operations are the largest single line of cost — site selection, patient recruitment, monitoring, data management, and trial conduct are operationally intense and the largest leverage on cycle time.
  • AI-native drug discovery competitors have raised billions on the bet that ML on biological data structurally compresses early R&D — the incumbent biotech has to absorb the AI capability without disrupting the regulated infrastructure already built.
Section 1 of 4 · Source of Truth0/8 answered

Source of Truth

Whether your operational data lives in one place or is scattered across tools.

1.Where does your core operational data live?
2.How many tools/spreadsheets hold 'the truth' for one workflow?

More tools for Biotech